Sigilon Therapeutics — Q2 2021 Earnings Presentation
30 slides from Sigilon Therapeutics's earnings presentation, Aug 10, 2021
Slide 1: Advancing Potential Functional Cures for Patients With Chronic Diseases
Advancing Potential Functional Cures for Patients With Chronic Diseases ©2021 Sigilon Therapeutics, Inc. August 2021 0
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Sigilon Therapeutics, Inc. (“we,” “us,” “our,” “Sigilon” or the “Company”) and is made for informational purposes only and not for any other purpose. Certain information contained in this presentation and statements made orally during this presentati
Slide 3: Sigilon Therapeutics Designed to Develop Functional Cures
SHIELDED LIVING THERAPEUTICS PLATFORM Sigilon Therapeutics Designed to Develop Functional Cures • Non-viral engineered cell-based therapy • No interference with patient’s DNA • Redosable and retrievable • No immunosuppression required • Scalable and flexible manufacturing 2 2
Slide 4: Our Company History
2020 Our Company History 2018 – 2019 2016 - 2017 1980 - 2015 Sigilon created by Flagship Pioneering Foundational partnership Developed our modular platform Hemophilia A Orphan Drug Designation (FDA) Key publications in peer-reviewed journal, Nature Seminal work by Drs. Robert (Bob) Langer and Daniel
Slide 5: 2021 Highlights
2021 Highlights •$372 million in funding to date •Completed IPO in December 2020 with $144.9 million in gross proceeds (priced at $18) •Current cash runway into Q4 2022 (~$162 million at the end of Q2 21) •Phase 1/2 study of SIG-001 (Hem A) on clinical hold due to SAE; investigation of potential con
Slide 6: Modular SLTx Product Platform
++ 1. Cells Selection criteria based on: Safety Durability Scalability Ability to switch transgene allows for plug‐n‐play 3 pillars of our modular platform technology Modular SLTx Product Platform From Cell Function to Potential Functional Cure 2. Sphere 3. Manufacturing Process Dual layer sph
Slide 7: Addressing a Broad Range of Chronic Diseases
PROGRAM CELL PRODUCT DISCOVERY LEAD OPTIMIZATION IND ENABLING PHASE 1/2 PHASE 3 Rare Blood Disorders SIG-001 – Hemophilia A BDD-FVIII SIG-009 – FVII Deficiency FVII SIG-003 – Hemophilia B Padua-FIX Lysosomal Diseases SIG-005 – MPS-1 Human IDUA SIG-007 – Fabry Human GLA SIG-018 – MPS-2 Human IDS SIG-
Slide 8: Broad and Deep IP Portfolio
Broad and Deep IP Portfolio* *As of 30 June 2021; expiry assumes 20 year term for issued patents, additional term for patent term extensions may be available in some countries 30 Patent Families • 9 families licensed from MIT • Expiry between 2032 and 2038 • 21 families owned by Sigilon • Expiry bet
Slide 9: Industry Leaders with Proven Track Record of Driving Value
Industry Leaders with Proven Track Record of Driving Value Rogerio Vivaldi, MD, MBA President, CEO Bernd Kullmann, MBA VP, Head of Mfg / Supply Chain Vanya Sagar, MPA Chief Human Resources Officer Olivia Kelly, PhD VP, Head of Diabetes Research Melodie Henderson, JD VP, Intellectual Property Counsel
Slide 10: Platform Preclinical Programs
Platform Preclinical Programs NHP studies in Hem A (SIG-001) and MPS-I (SIG-005) confirmed bioavailability in plasma Multiple rodent studies in Hem A, MPS-1, Fabry, FVII, & Hem B demonstrated bioavailability in plasma BIOAVAILABILITY FROM IP PLASMA Product delivery method evaluated in mice,
Slide 11: Bioavailability Demonstrated in NHP for SIG-001 and SIG-005
Bioavailability Demonstrated in NHP for SIG-001 and SIG-005 10 110 1 100 1 100 2 1003 1102 110 3 0 10 20 30 40 50 FVIII Expression in Plasma (%) Spheres expressing human protein administered intraperitoneally in cynomolgus monkeys Quantifiable plasma levels achieved for both programs demonstrate bio
Slide 12: Efficacy Demonstrated in Lysosomal Disease Mice Across Three Programs
Efficacy Demonstrated in Lysosomal Disease Mice Across Three Programs 11 U/mg SIG‐005 MPS‐I Program Heparan Sulfate Level in Liver SIG‐007 Fabry Program GLA Activity in Liver SIG‐018 MPS‐2 Program Heparan Sulfate Level in Liver Low dose SIG-007 Med dose SIG-007 High dose SIG-007 Fabrazyme ng HS/mg t
Slide 13: SLTx Designed to Provide Important Advantages Versus Gene Therapy
SLTx Designed to Provide Important Advantages Versus Gene Therapy 12 Recent Gene Therapy Setbacks: Declining efficacy (including loss of all expression) Unpredictable overdosing Insertional mutagenesis risk with AAV (genotoxicity risk) Insertional mutagenesis risk with alkylating agents Se
Slide 14: SIG-001 for Hem A: Efficacy, Durability and Controllability Observed in Preclinical Studies
SIG-001 for Hem A: Efficacy, Durability and Controllability Observed in Preclinical Studies * -Statistically significant reduction in bleeding time relative to HA + wt (p<0.05). Bleeding time (in sec) 0 500 1000 1500 2000 WT Mice HA Mice + Control Spheres HA Mice + SIG-001 * Efficacious Controll
Slide 15: SIG-001 Phase 1/2 Dose Escalation Study
SIG-001 Phase 1/2 Dose Escalation Study Rare Blood Disorders • Clinical Hold Investigation: • SAE on patient 3 due to low titer inhibitor • Investigation of potential contributing factors ongoing • Additional analyses on clinical samples • Safety Review Committee monitoring • Significant Milestones:
Slide 16: Lysosomal Diseases
Lysosomal Diseases • Our modular platform can be applied across a range of lysosomal storage diseases and lead to significant improvements in speed to clinic • In preclinical studies, platform cells produce sustained high levels of biochemically active enzyme with characteristics identical to the de
Slide 17: SIG-005: Phenotypic Correction in Bone After Months Of Treatment in Mice With MPS-1
SIG-005: Phenotypic Correction in Bone After 5 Months Of Treatment in Mice With MPS-1 Reduced thickness in cortical areas Sustained reduction in GAGs Reduction in bone volume Mineral density, mgHA/cm3 Reduction in mineral density Female Male 0.8 1.0 1.2 1.4 1.6 Average area of bone, Ct.Ar p=0.089 p=
Slide 18: SIG-005: Substrate Reduction in Different Tissues in Mice with MPS-1
SIG-005: Substrate Reduction in Different Tissues after 5 Months of Treatment in Mice with MPS-1 Heart Kidney Liver Lung Treated Untreated Zeiss 20x; Alcian blue; Black arrow indicates substrate (Untx: G7-1; Tx: G3-1); * Glomerulus; * Bronchiole Lysosomal Diseases 17
Slide 19: SIG-005 Cryopreserved Drug Substance Decreases Manufacturing Lead Time by 80%
SIG-005 Cryopreserved Drug Substance Decreases Manufacturing Lead Time by 80% SIG‐005 MPS‐I Program Heparan Sulfate Level in Liver ng HS/mg total protein Equivalent substrate reduction for fresh and cryopreserved drug substance in SIG-005 spheres SIG‐001 (Fresh DS) SIG‐005 (Cryo DS) Lysosomal Diseas
Slide 20: SIG-005 Clinical Design and Status
SIG-005 Clinical Design and Status • Filed CTA (UK) in June 2021 and CTA (Brazil) in July 2021 • Next step expected to include IND filing in the US 19 Lysosomal Diseases * Dose escalation may occur • Phase 1/2 Safety and Dose Ranging Study • Open‐label; Sequential dose escalation • N = 9 patients •
Slide 21: SIG-007: Reduction Lyso-gb3 Across Tissues in Mice With Fabry
SIG-007: Reduction Lyso-gb3 Across Tissues in Mice With Fabry After 1 Month of Treatment Lysosomal Diseases Presented at the 17th Annual WORLDSymposium™ February 8th -12 th 2021, virtually. N=6/group; L:low dose; M: medium dose; H:high dose; Unt: untreated; unpaired t‐test vs untreated: ****p<0.001;
Slide 22: SIG-018: Substrate Reduction Across Tissues in Mice With MPS-2
SIG-018: Substrate Reduction Across Tissues in Mice With MPS-2 Mouse Tissues After 1 Week of Treatment LMHSham 0 5 10 50 100 150 **** **** **** ng HS/mg total protein as % of sham LMHSham 0 50 100 150 200 ng HS/mg total protein as % of sham ** * ** ng HS/mg total protein as % of sham LMHSham 0 50 10
Slide 23: SIG-020: Substrate Reduction Across Tissues in Mice With MPS-6
SIG-020: Substrate Reduction Across Tissues in Mice With MPS-6 After 7 Days of Treatment Lysosomal Diseases 22
Slide 24: Sigilon and Lilly Collaborating to Develop Potential Functional Cure for Type 1 Diabetes
Sigilon and Lilly Collaborating to Develop Potential Functional Cure for Type 1 Diabetes • Sigilon is responsible for execution of the program through IND • Eli Lilly, a global leader in diabetes, will develop and commercialize program worldwide if approved • Financial Terms: • $75 million initial c
Slide 25: Diabetes Program Progresses Toward IND
Diabetes Program Progresses Toward IND Blood Glucose (mg/dL) Mean ± SEM 600 500 400 300 200 100 0 Time (Days) 600 500 400 300 200 100 0 330 300 270 240 210 180 150 120 90 60 30 0 Review Article by Langer R; Molecular Frontiers Journal (2017) Rat donor islets in STZ mice (12 months) Endocrine Disease
Slide 26: Developing Products for Liver Diseases
Sa li ne Co n A 3T3 mIL-10 + ConA 0 2 4 6 Developing Products for Liver Diseases 25 Liver Necrosis Immune Mediated Diseases • Autoimmune hepatitis • Hepatocyte destruction by pro- inflammatory cytokines • Pathology shared with common liver diseases • IL-10 • Cytokine that resolves inflammation • IL-
Slide 27: Developing Products for Graft Versus Host Disease
Plasma Concentration CTLA ‐ 4 ‐ Ig ( g/ml) Days Post‐Implantation Developing Products for Graft Versus Host Disease Immune Mediated Diseases Loss of Body Weight Survival Sustained production of CTLA-4-Ig by SLTx Spheres No Treatment Controls Control Spheres CTLA‐4‐Ig Spheres SLTx mediated CTLA-4-I
Slide 28: Manufacturing Optimization for Off-the-Shelf Product at Scale
Manufacturing Optimization for Off-the-Shelf Product at Scale 27 Bulk Drug Product Manufacturing Cryopreservation 28-day fresh cell culture process transitioning to cryopreserved off-the-shelf product 1 Day Manufacturing Automated Encapsulation Scale & Speed Large scale production for > 4L Drug Prod
Slide 29: Multiple Milestones Targeted
Multiple Milestones Targeted Initiating 2nd Clinical Program H2 21 •Up to 9-month follow-up Phase 1/2 data (3 patients): SIG-001/Hem A •Completion of the Clinical Hold investigation •Phase 1/2 Initiation: SIG-005/MPS-1 (pending CTA/IND approval) Potential for Three Clinical Programs 2022 •IND/CTA su
Slide 30: Thank You
Thank You